Status:
UNKNOWN
IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.
Lead Sponsor:
Versailles Hospital
Conditions:
SARS Virus
Eligibility:
All Genders
70+ years
Phase:
PHASE2
Brief Summary
High-throughput screening studies identified Abl kinase inhibitors (including imatinib) as inhibitors of coronaviruses SARS and MERS. The SARS-CoV-2 coronavirus depend on Abl2 kinase activity to fuse ...
Eligibility Criteria
Inclusion
- . Patient aged \> 70y 2. Patient with a documented COVID-19 disease by SARS-CoV-2 RT-PCR (if no test is available, suspected COVID-19 disease on CT SCAN).
- 3\. Initial phase (≤ 7 days) of COVID-19 disease 4. Non severe COVID-19 disease 5. Signed informe consent
Exclusion
- Patient in palliative care
- Severe COVID-19 disease (SpO2 ≤ 94% with O2 ≥ 5 l/min)
- Contra-indication to imatinib
- Therapy with Warfarin (Heparin allowed)
- Stage II to IV congestive heart failure (CHF) as determined by the New York Heart Association (NYHA)
- Peripheral edema grade \> 2
- Known HBV, HBC or HIV infection
- Known hepatic failure
- Patient under legal protection
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT04357613
Start Date
September 1 2020
End Date
December 1 2021
Last Update
August 7 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Bordeaux
Bordeaux, France
2
CH de Versailles
Le Chesnay, France